STOCK TITAN

[Form 3] Lucid Diagnostics Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

John R. Palumbo, a director of Lucid Diagnostics Inc. (LUCD), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 47,857 shares of common stock. The transaction date requiring the filing is 09/22/2025. The Form 3 was signed by Michael A. Gordon by power of attorney on 10/07/2025. No derivative securities or additional holdings were reported on this form.

John R. Palumbo, direttore di Lucid Diagnostics Inc. (LUCD), ha presentato una Dichiarazione Iniziale di Proprietà Beneficiaria riportando la proprietà diretta di 47.857 azioni ordinarie. La data della transazione che richiede la presentazione è 09/22/2025. Il Modulo 3 è stato firmato da Michael A. Gordon per procura in data 10/07/2025. Non sono stati riportati derivati o ulteriori partecipazioni in questo modulo.

John R. Palumbo, director de Lucid Diagnostics Inc. (LUCD), presentó una Declaración Inicial de Propiedad Beneficiaria reportando la titularidad directa de 47,857 acciones comunes. La fecha de la transacción que exige la presentación es 09/22/2025. El Formulario 3 fue firmado por Michael A. Gordon por poder el 10/07/2025. No se reportaron valores derivados ni participaciones adicionales en este formulario.

존 R. 팔룸보루시드 다이애그노스틱스 주식회사(LUCD)의 이사로서 직접 보유 주식 47,857주를 보고하는 초기 이익소유권 고지서를 제출했습니다. 제출을 요하는 거래 날짜는 2025-09-22입니다. 양식 3은 마이클 A. 고든이 위임장으로 2025-10-07에 서명했습니다. 이 양식에는 파생증권이나 추가 보유 주식은 보고되지 않았습니다.

John R. Palumbo, directeur de Lucid Diagnostics Inc. (LUCD), a déposé une Déclaration initiale de propriété bénéficiaire indiquant la détention directe de 47 857 actions ordinaires. La date de transaction nécessitant le dépôt est 09/22/2025. Le Formulaire 3 a été signé par Michael A. Gordon par procuration le 10/07/2025. Aucun titre dérivé ni participation supplémentaire n’a été signalé dans ce formulaire.

John R. Palumbo, Direktor von Lucid Diagnostics Inc. (LUCD), hat eine Initial Statement of Beneficial Ownership eingereicht, die direkte Eigentümerschaft von 47.857 Stammaktien angibt. Das für die Einreichung erforderliche Transaktionsdatum ist 09/22/2025. Das Formular 3 wurde von Michael A. Gordon per Vollmacht am 10/07/2025 unterzeichnet. In diesem Formular wurden keine derivativen Wertpapiere oder zusätzliche Beteiligungen gemeldet.

جون ر. بالومبو، مدير في لوسيد دايتكس إنك. (LUCD)، قدم بياناً ابتدائياً لملكية المستفيد يذكر الملكية المباشرة لـ 47,857 سهماً من الأسهم العادية. تاريخ المعاملة الذي يستلزم التقديم هو 09/22/2025. كما أن النموذج 3 وقع عليه مايكل أ. جوردون بتوكيل رسمي في تاريخ 10/07/2025. لم تُبلغ أي أوراق مالية مشتقة أو حيازات إضافية في هذا النموذج.

John R. PalumboLucid Diagnostics Inc. (LUCD) 的董事,提交了初始受益所有权声明,报告直接持有 47,857 股普通股。需要提交的交易日期为 09/22/2025。Form 3 由 Michael A. Gordon 代表授权于 10/07/2025 签署。本表未报告任何衍生证券或额外持股。

Positive
  • Director ownership of 47,857 shares aligns management interests with shareholders
  • Timely Section 16 disclosure filed for the 09/22/2025 event
Negative
  • None.

Insights

Director filing shows modest direct stake, signaling basic insider alignment.

The filing records a direct holding of 47,857 common shares by a company director, which is a routine disclosure under Section 16. This level of ownership provides a measurable, though not controlling, equity stake that aligns the director with shareholder outcomes.

Filing timeliness and the use of a power of attorney for signature are procedural details to note; there are no derivatives or additional appointments disclosed. Watch for future Forms 4 or 5 that would show changes in this position or option grants within the next reporting cycle.

John R. Palumbo, direttore di Lucid Diagnostics Inc. (LUCD), ha presentato una Dichiarazione Iniziale di Proprietà Beneficiaria riportando la proprietà diretta di 47.857 azioni ordinarie. La data della transazione che richiede la presentazione è 09/22/2025. Il Modulo 3 è stato firmato da Michael A. Gordon per procura in data 10/07/2025. Non sono stati riportati derivati o ulteriori partecipazioni in questo modulo.

John R. Palumbo, director de Lucid Diagnostics Inc. (LUCD), presentó una Declaración Inicial de Propiedad Beneficiaria reportando la titularidad directa de 47,857 acciones comunes. La fecha de la transacción que exige la presentación es 09/22/2025. El Formulario 3 fue firmado por Michael A. Gordon por poder el 10/07/2025. No se reportaron valores derivados ni participaciones adicionales en este formulario.

존 R. 팔룸보루시드 다이애그노스틱스 주식회사(LUCD)의 이사로서 직접 보유 주식 47,857주를 보고하는 초기 이익소유권 고지서를 제출했습니다. 제출을 요하는 거래 날짜는 2025-09-22입니다. 양식 3은 마이클 A. 고든이 위임장으로 2025-10-07에 서명했습니다. 이 양식에는 파생증권이나 추가 보유 주식은 보고되지 않았습니다.

John R. Palumbo, directeur de Lucid Diagnostics Inc. (LUCD), a déposé une Déclaration initiale de propriété bénéficiaire indiquant la détention directe de 47 857 actions ordinaires. La date de transaction nécessitant le dépôt est 09/22/2025. Le Formulaire 3 a été signé par Michael A. Gordon par procuration le 10/07/2025. Aucun titre dérivé ni participation supplémentaire n’a été signalé dans ce formulaire.

John R. Palumbo, Direktor von Lucid Diagnostics Inc. (LUCD), hat eine Initial Statement of Beneficial Ownership eingereicht, die direkte Eigentümerschaft von 47.857 Stammaktien angibt. Das für die Einreichung erforderliche Transaktionsdatum ist 09/22/2025. Das Formular 3 wurde von Michael A. Gordon per Vollmacht am 10/07/2025 unterzeichnet. In diesem Formular wurden keine derivativen Wertpapiere oder zusätzliche Beteiligungen gemeldet.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
PALUMBO JOHN R

(Last) (First) (Middle)
360 MADISON AVENUE
25TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/22/2025
3. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 47,857 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Michael A. Gordon, by power of attorney 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for LUCD disclose?

The Form 3 reports that director John R. Palumbo directly owns 47,857 shares of Lucid Diagnostics common stock.

When is the event date listed on the LUCD Form 3?

The event requiring the filing is dated 09/22/2025.

Who signed the Form 3 for John R. Palumbo?

The form was signed by Michael A. Gordon by power of attorney on 10/07/2025.

Were any derivative securities reported on this Form 3 for LUCD?

No. The filing shows only non-derivative common stock holdings and lists no derivative securities.

Is the reported ownership direct or indirect?

The filing specifies the ownership as direct (D) for the 47,857 shares.
Lucid Diagnostics Inc.

NASDAQ:LUCD

LUCD Rankings

LUCD Latest News

LUCD Latest SEC Filings

LUCD Stock Data

125.33M
96.00M
34.55%
18.87%
5.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK